New treatment for heart failure in Duchenne muscular dystrophy patients
IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients
This study is testing a new under-the-skin treatment for heart problems caused by Duchenne muscular dystrophy (DMD) to see if it can help improve heart function and possibly help patients live longer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Revidia Therapeutics, INC NIH-funded |
| Lab location | 1 site (Ellsworth, UNITED STATES) |
| Project ID | NIH-10913659 on NIH RePORTER |
What this research studies
This research focuses on developing a new subcutaneous treatment for heart failure caused by cardiomyopathy in patients with Duchenne muscular dystrophy (DMD). The approach involves a small molecule called MSI-1436, which has shown safety in humans and works by inhibiting a specific enzyme that hinders the body's natural repair processes. By reactivating these processes, the treatment aims to improve heart function and potentially extend the lives of DMD patients. The research is crucial as there are currently no approved medications specifically for DMD-related cardiomyopathy.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with Duchenne muscular dystrophy who are experiencing heart failure or cardiomyopathy.
Not a fit: Patients with other forms of heart failure not related to Duchenne muscular dystrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a much-needed treatment option for heart failure in DMD patients, potentially improving their quality of life and longevity.
How similar studies have performed: While there has been limited research specifically targeting DMD cardiomyopathy, the approach of using small molecules to enhance cardiac repair has shown promise in other contexts.
Where this research is happening
Ellsworth, UNITED STATES
- Revidia Therapeutics, INC — Ellsworth, United States (Active)
Researchers
- Principal investigator: Strange, Kevin — Revidia Therapeutics, INC
- Study coordinator: Strange, Kevin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.